Extract from the Register for Unitary Patent Protection

UP About this file: EP3337828  C0

EP3337828 - ANTI-PCSK9 INHIBITORY ANTIBODIES FOR TREATING PATIENTS WITH HYPERLIPIDEMIA UNDERGOING LIPOPROTEIN APHERESIS [Right-click to bookmark this link]
StatusUnitary effect registered
Database last updated on 08.04.2026
FormerRequest for unitary effect filed
Status updated on  24.09.2025
Most recent event   Tooltip20.02.2026Change or deletion: representative for unitary effectpublished on 25.03.2026  [2026/13]
Proprietor(s)For all participating member states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
[2025/44]  
Inventor(s)01 / PORDY, Robert C.
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
02 / MANVELIAN, Garen
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
 [2018/26]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2026/13]
Former [2026/08]Kilburn & Strode LLP
Lacon London
84 Theobalds Road
Holborn
London WC1X 8NL / GB
Former [2025/44]Mackie, Heather, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
Application number, filing date16758019.017.08.2016
[2018/26]
WO2016US47257
Procedural languageEN
(Principal) place of business   Tooltip
on the date of filing
 Principal place of businessTooltip
Unitary Patent Protection23.09.2025Date of request for unitary effect [2025/44]
30.09.2025Decision on the request for unitary effect:  Positive [2025/44]
30.09.2025Date of registration  [2025/44]
27.08.2025Date of legal effect  [2025/44]
Member States covered by Unitary  Tooltip
Patent Protection
30.09.2025AT, BE, BG, DE, DK, EE, FI, FR, IT, LT, LU, LV, MT, NL, PT, RO, SE, SI  [2025/44]
PublicationType: B1 Patent specification 
No.:EP3337828
Date:27.08.2025
Language:EN
[2025/35]
The European Patent Register provides the information on unitary patent protection required under R. 16(1) UPR. "Status" and "Most recent event" are not entries required under R. 16(1) UPR and should therefore be regarded as additional information only.

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes. Please refer to the relevant national patent authority for SPC data.